Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.

@article{Ramirez2007AntiIL2II,
  title={Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.},
  author={Carlo Gerardo B. Ramirez and Cataldo Doria and Fabrizio di Francesco and Maurizio Iaria and Yoogoo Kang and Ignazio Roberto Marino},
  journal={The Journal of surgical research},
  year={2007},
  volume={138 2},
  pages={198-204}
}
BACKGROUND Induction with the use of monoclonal antibodies targeting the alpha-chain (CD25) of the high-affinity IL2 receptor may avoid many of the adverse events associated with polyclonal antibodies and significantly impact on rejection-free long-term survival in orthotopic liver transplantation (OLT). METHODS Forty-two consecutive deceased donor primary OLT were retrospectively analyzed. All patients received two 20-mg doses of basiliximab (days 0 and 4 after OLT) followed by tacrolimus (0… CONTINUE READING